Skip to main content

Advertisement

Log in

Trastuzumab administration during pregnancy: a systematic review and meta-analysis

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Landmark studies have established trastuzumab in the treatment of HER2-positive breast cancer. The present systematic review and meta-analysis aims to synthesize all available data, so as to evaluate the safety of trastuzumab during pregnancy. This study was performed in accordance with the PRISMA guidelines. All studies that examined the safety of trastuzumab administered during pregnancy, regardless of sample size, were considered eligible. Overall, 17 studies (18 pregnancies; 19 newborns) were included. In 55.6 % of cases, trastuzumab was administered in the metastatic setting. The mean duration of trastuzumab administration was 14.8 weeks. Occurrence of oligohydramnios/anhydramnios (O/A) was the most common (61.1 %) adverse event. 73.3 % of pregnancies exposed to trastuzumab during the second/third trimester were complicated with O/A; the respective rate of pregnancies exposed to trastuzumab exclusively during the first trimester was 0 % (P = 0.043). The mean GA at delivery was 33.8 weeks, and the mean weight of babies at delivery was 2,261 gr. In 52.6 % of cases, a healthy neonate was born. At the long-term evaluation, all children without problems at birth were healthy with a median follow-up of 9 months, while four out of nine children facing troubles at birth were dead within an interval ranging between birth and 5.25 months. All children exposed to trastuzumab in utero exclusively in the first trimester were completely healthy at birth. Trastuzumab should not be administered during pregnancy. However, for women who become accidentally pregnant during trastuzumab administration and wish to continue pregnancy, trastuzumab should be stopped and pregnancy could be allowed to continue.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Pentheroudakis G, Orecchia R, Hoekstra HJ et al (2010) Cancer, fertility and pregnancy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v266–v273

    Article  PubMed  Google Scholar 

  2. Mir O, Berveiller P, Ropert S et al (2008) Emerging therapeutic options for breast cancer chemotherapy during pregnancy. Ann Oncol 19:607–613

    Article  PubMed  CAS  Google Scholar 

  3. Howlader N, Noone AM, Krapcho M, et al (2011) SEER cancer statistics review, 1975–2008. National Cancer Institute. Bethesda. http://seer.cancer.gov/csr/1975_2008/, based on November 2010 SEER data submission, posted to the SEER web site

  4. Gianni L, Dafni U, Gelber RD et al (2011) Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:236–244

    Article  PubMed  CAS  Google Scholar 

  5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672

    Article  PubMed  CAS  Google Scholar 

  6. Untch M, Fasching PA, Konecny GE et al (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29:3351–3357

    Article  PubMed  CAS  Google Scholar 

  7. Valero V, Forbes J, Pegram MD et al (2011) Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 29:149–156

    Article  PubMed  CAS  Google Scholar 

  8. Andersson M, Lidbrink E, Bjerre K et al (2011) Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. J Clin Oncol 29:264–271

    Article  PubMed  CAS  Google Scholar 

  9. NCCN Clinical Practice Guidelines in Oncology (2012) Breast cancer, version 2.2012. www.nccn.com

  10. Azim HA Jr, Azim H, Peccatori FA (2010) Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol 6:821–826

    Article  PubMed  Google Scholar 

  11. Abusief ME, Missmer SA, Ginsburg ES et al (2010) The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 116:791–798

    Article  PubMed  CAS  Google Scholar 

  12. Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34

    Article  PubMed  Google Scholar 

  13. Gottschalk I, Berg C, Harbeck N et al (2011) Fetal renal insufficiency following trastuzumab treatment for breast cancer in pregnancy: case report und review of the current literature. Breast Care (Basel) 6:475–478

    Article  Google Scholar 

  14. El-Safadi S, Wuesten O, Muenstedt K (2012) Primary diagnosis of metastatic breast cancer in the third trimester of pregnancy: a case report and review of the literature. J Obstet Gynaecol Res 38:589–592

    Article  Google Scholar 

  15. Mandrawa CL, Stewart J, Fabinyi GC et al (2011) A case study of trastuzumab treatment for metastatic breast cancer in pregnancy: fetal risks and management of cerebral metastases. Aust N Z J Obstet Gynaecol 51:372–376

    Article  PubMed  Google Scholar 

  16. Goodyer MJ, Ismail JR, O’Reilly SP et al (2009) Safety of trastuzumab (Herceptin) during pregnancy: two case reports. Cases J 2:9329

    Article  PubMed  Google Scholar 

  17. Beale JM, Tuohy J, McDowell SJ (2009) Herceptin (trastuzumab) therapy in a twin pregnancy with associated oligohydramnios. Am J Obstet Gynecol 201:e13–e14

    Article  PubMed  Google Scholar 

  18. Weber-Schoendorfer C, Schaefer C (2008) Trastuzumab exposure during pregnancy. Reprod Toxicol 25:390–391; author reply 392

    Google Scholar 

  19. Pant S, Landon MB, Blumenfeld M et al (2008) Treatment of breast cancer with trastuzumab during pregnancy. J Clin Oncol 26:1567–1569

    Article  PubMed  Google Scholar 

  20. Witzel ID, Müller V, Harps E et al (2008) Trastuzumab in pregnancy associated with poor fetal outcome. Ann Oncol 19:191–192

    Article  PubMed  CAS  Google Scholar 

  21. Sekar R, Stone PR (2007) Trastuzumab use for metastatic breast cancer in pregnancy. Obstet Gynecol 110:507–510

    Article  PubMed  Google Scholar 

  22. Shrim A, Garcia-Bournissen F, Maxwell C et al (2007) Favorable pregnancy outcome following Trastuzumab (Herceptin) use during pregnancy- Case report and updated literature review. Reprod Toxicol 23:611–613

    Article  PubMed  CAS  Google Scholar 

  23. Bader AA, Schlembach D, Tamussino KF et al (2007) Anhydramnios associated with administration of trastuzumab and paclitaxel for metastatic breast cancer during pregnancy. Lancet Oncol 8:79–81

    Article  PubMed  Google Scholar 

  24. Waterston AM, Graham J (2006) Effect of adjuvant trastuzumab on pregnancy. J Clin Oncol 24:321–322

    Article  PubMed  Google Scholar 

  25. Fanale MA, Uyei AR, Theriault RL et al (2005) Treatment of metastatic breast cancer with trastuzumab and vinorelbine during pregnancy. Clin Breast Cancer 6:354–356

    Article  PubMed  CAS  Google Scholar 

  26. Watson WJ (2005) Herceptin (trastuzumab) therapy during pregnancy: association with reversible anhydramnios. Obstet Gynecol 105:642–643

    Article  PubMed  Google Scholar 

  27. Azim HA Jr, Peccatori FA, Liptrott SJ et al (2009) Breast cancer and pregnancy: how safe is trastuzumab? Nat Rev Clin Oncol 6:367–370

    Article  PubMed  CAS  Google Scholar 

  28. Warraich Q, Smith N (2009) Herceptin therapy in pregnancy: continuation of pregnancy in the presence of anhydramnios. J Obstet Gynaecol 29:147–148

    Article  PubMed  CAS  Google Scholar 

  29. Roberts NJ, Auld BJ (2010) Trastuzamab (Herceptin)-related cardiotoxicity in pregnancy. J R Soc Med 103:157–159

    Article  PubMed  Google Scholar 

  30. Azim HA Jr, Peccatori FA, Pavlidis N (2010) Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: solid tumors. Cancer Treat Rev 36:101–109

    Article  PubMed  CAS  Google Scholar 

  31. Zagouri F, Sergentanis TN, Chrysikos D et al (2012) Taxanes for ovarian cancer during pregnancy: a systematic review. Oncology 83:234–238

    Article  PubMed  CAS  Google Scholar 

  32. Zagouri F, Sergentanis TN, Chrysikos D et al (2012) Taxanes for breast cancer during pregnancy: a systematic review. Clin Breast Cancer [Epub Ahead of print]

  33. Pentsuk N, van der Laan JW (2009) An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol 86:328–344

    Article  PubMed  CAS  Google Scholar 

  34. Malek A (2003) Ex vivo human placenta models: transport of immunoglobulin G and its subclasses. Vaccine 21:3362–3364

    Article  PubMed  CAS  Google Scholar 

  35. Kilpatrick SJ (1997) Therapeutic interventions for oligohydramnios: amnioinfusion and maternal hydration. Clin Obstet Gynecol 40:328–336

    Article  PubMed  CAS  Google Scholar 

  36. Vanderheyden T, Kumar S, Fisk NM (2003) Fetal renal impairment. Semin Neonatol 8:279–289

    Article  PubMed  Google Scholar 

  37. Goodyer PR, Cybulsky A, Goodyer C (1993) Expression of the epidermal growth factor receptor in fetal kidney. Pediatr Nephrol 7:612–615

    Article  PubMed  CAS  Google Scholar 

  38. Jokhi PP, King A, Loke YW (1994) Reciprocal expression of epidermal growth factor receptor (EGF-R) and c-erbB2 by non-invasive and invasive human trophoblast populations. Cytokine 6:433–442

    Article  PubMed  CAS  Google Scholar 

  39. Lee KF, Simon H, Chen H et al (1995) Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 378:394–398

    Article  PubMed  CAS  Google Scholar 

  40. Azim HA Jr, Metzger-Filho O, de Azambuja E et al (2012) Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01–01). Breast Cancer Res Treat 133:387–391

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

FZ is receiving a research grant from HeSMO.

Conflict of interest

The authors have declared no conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Flora Zagouri.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zagouri, F., Sergentanis, T.N., Chrysikos, D. et al. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res Treat 137, 349–357 (2013). https://doi.org/10.1007/s10549-012-2368-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-012-2368-y

Keywords

Navigation